miR-146a-/-小鼠模型揭示NF-κB抑制可逆转炎症驱动的骨髓纤维化样表型
研究使用缺乏驱动突变的miR-146a-/-(KO)小鼠骨髓纤维化(MF)样模型,测试JAK1/2抑制剂芦可替尼、NF-κB抑制剂BMS-345541、两药联合及JAK2/IRAK1双抑制剂帕克替尼的疗效。结果显示仅NF-κB抑制(BMS-345541单用或联合、帕克替尼)可减少髓外造血、骨髓纤维化和骨硬化并减轻炎症,但联合治疗通过诱导骨髓发育不全加重贫血。
要点
- 在miR-146a-/-小鼠MF样模型中,NF-κB抑制可减少骨髓纤维化和骨硬化。
- 帕克替尼改善贫血并逆转血小板减少,但联合BMS-345541加重贫血。
- NF-κB抑制在体外和体内均降低疾病负荷和骨髓纤维化。
核心结论
- NF-κB抑制在体外和体内降低疾病负荷和骨髓纤维化,可能为骨髓纤维化患者提供获益。
研究设计与样本
- 使用缺乏驱动突变的miR-146a-/-(KO)小鼠骨髓纤维化样模型。
- 测试芦可替尼、BMS-345541、两者联合及帕克替尼的疗效。
主要发现
- 所有治疗均缩小脾脏并部分恢复其结构。
- 仅NF-κB抑制(BMS-345541单用或联合、帕克替尼)减少髓外造血、骨髓纤维化和骨硬化,并减轻IL-1β和TNFα相关的炎症状态。
- 帕克替尼改善贫血并逆转血小板减少,而联合治疗通过诱导骨髓发育不全加重贫血。
- 两种治疗选择在JAK2V617F驱动的克隆性造血背景下均降低NF-κB和JAK/STAT信号。
- 联合治疗在模拟JAK2驱动纤维化的体外模型中减少COL1A1和IL-6产生。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Emerging evidence shows the crucial role of inflammation (particularly NF-κB pathway) in the development and progression of myelofibrosis (MF), becoming a promising therapeutic target. Furthermore, tailoring treatment with currently available JAK inhibitors (such as ruxolitinib or fedratinib) does not modify the natural history of the disease and has important limitations, including cytopenias. Since recent studies have highlighted the role of miR-146a, a negative regulator of the NF-κB pathway, in the pathogenesis of MF; here we used miR-146a-/- (KO) mice, a MF-like model lacking driver mutations, to investigate whether pharmacological inhibition of JAK/STAT and/or NF-κB pathways may reverse the myelofibrotic phenotype of these mice. Specifically, we tested the JAK1/2 inhibitor, ruxolitinib; the NF-κB inhibitor via IKKα/β, BMS-345541; both inhibitors in combination; or a dual inhibitor of both pathways (JAK2/IRAK1), pacritinib. Although all treatments decreased spleen size and partially recovered its architecture, only NF-κB inhibition, either using BMS-345541 (alone or in combination) or pacritinib, resulted in a reduction of extramedullary hematopoiesis, bone marrow (BM) fibrosis and osteosclerosis, along with an attenuation of the exacerbated inflammatory state (via IL-1β and TNFα). However, although dual inhibitor improved anemia and reversed thrombocytopenia, the combined therapy worsened anemia by inducing BM hypoplasia. Both therapeutic options reduced NF-κB and JAK/STAT signaling in a context of JAK2V617F-driven clonal hematopoiesis. Additionally, combined treatment reduced both COL1A1 and IL-6 production in an in vitro model mimicking JAK2-driven fibrosis. In conclusion, NF-κB inhibition reduces, in vitro and in vivo, disease burden and BM fibrosis, which could provide benefits in myelofibrosis patients.
引用
- Cuenca-Zamora EJ, Guijarro-Carrillo PJ, López-Poveda MJ, et al. miR-146a-/- mice model reveals that NF-κB inhibition reverts inflammation-driven myelofibrosis-like phenotype. Am J Hematol. 2024. PMID: 38646919. doi:10.1002/ajh.27322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。